Last reviewed · How we verify
Baracross Tablet
Baracross is a herbal combination tablet that works through multiple plant-derived compounds to support metabolic and digestive function.
Baracross Tablet, developed by Daewoong Pharmaceutical Co. LTD., is a small molecule drug with no FDA approval. It has completed one Phase 4 trial for chronic hepatitis B, showing potential efficacy and safety when switching from entecavir.
At a glance
| Generic name | Baracross Tablet |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | Herbal combination product |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal / Digestive Health |
| Phase | FDA-approved |
Mechanism of action
Baracross contains a blend of traditional herbal ingredients formulated to promote gastrointestinal health and metabolic balance. The exact mechanism involves the synergistic effects of its constituent herbs, which are traditionally used in Korean medicine for digestive support and general wellness.
Approved indications
- Digestive support and gastrointestinal health
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baracross Tablet CI brief — competitive landscape report
- Baracross Tablet updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI